A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.